Background: Renal insufficiency is a common and severe complication of patients with
multiple myeloma. The aim of this study was to evaluate bortezomib-based treatment for …

This report presents the totality of evidence through a systematic review that assessed either
the efficacy or safety of bortezomib-based regimens in multiple myeloma with renal …

Background: Renal impairment (RI) is a common complication of multiple myeloma (MM).
Around 50% of patients with MM have RI at presentation, and up to 5% require dialysis …

Renal impairment (RI) is a severe complication throughout the course of multiple myeloma
(MM). Bortezomib has been shown to be highly active in MM patients with RI. We designed …

Background Renal impairment is a common feature in multiple myeloma and is considered
a poor prognostic factor. Aim To determine the impact of novel drugs (ie bortezomib …

Renal impairment is a major complication of multiple myeloma (MM) and is associated with
poor prognosis. Early effective treatment can lead to improvement in renal function, which is …

Purpose Renal impairment is a frequent complication of multiple myeloma (MM) and is
associated with significant morbidity and increased early death rate. Bortezomib is active …

Background Renal impairment is a common complication of multiple myeloma (MM) and is
related to shorter overall survival and increased rates of early death. Bortezomib is a new …

Renal impairment is associated with poor prognosis in multiple myeloma (MM). This
subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending …

Multiple myeloma (MM) is often associated with renal insufficiency (RI) which adversely
influences the prognosis. Several studies demonstrated that bortezomib can improve both …